Method and kit for the detection of pancreatic dysfunction
AssigneesToray Industries, Inc., National Cancer Center
InventorsMichimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
Life of this patent
Estimating the term…
Abstract
The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.
Claims1
A kit for the detection of pancreatic exocrine dysfunction, comprising one or more of a monoclonal antibody or a fragment thereof selected from the group consisting of
- an anti-Apolipoprotein A2-ATQ (anti-APOA2-ATQ) terminus monoclonal antibody or a fragment thereof and an anti-APOA2 non-terminus monoclonal antibody or a fragment thereof, wherein the ATQ is the amino acid sequence at the C-terminus of APOA2,
- wherein the anti-APOA2-ATQ terminus monoclonal antibody comprises the CDRs shown in the following (i) or (ii);
- (i) in the heavy chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
- 3, 4, and 5, respectively, and
- in the light chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOS:
- 6, 7, and 8, respectively, and
- (ii) in the heavy chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
- 9, 10, and 11, respectively, and
- in the light chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOS:
- 12, 13, and 14, respectively, and
- wherein the anti-APOA2 non-terminus monoclonal antibody comprises the CDRs shown in the following (iii) or (vi);
- (iii) in the heavy chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
- 15, 16, and 17, respectively, and
- in the light chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
- 18, 19, and 20, respectively, and
- (vi) in the heavy chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOS:
- 21, 22, and 23, respectively, and
- in the light chain, CDR1, CDR2, and CDR3 having the amino acid sequence represented by SEQ ID NOs:
- 24, 25, and 26, respectively.
Dependencies are inferred from the claim text.